| Literature DB >> 24124616 |
Yu-Chun Chen1, Shih-Chieh Chang, Christy Pu, Gau-Jun Tang.
Abstract
OBJECTIVES: We investigated the effect of a nationwide educational program following surviving sepsis campaign (SSC) guidelines. Physicians' clinical practice in sepsis care and patient mortality rate for severe sepsis were analyzed using a nationally representative cohort.Entities:
Mesh:
Year: 2013 PMID: 24124616 PMCID: PMC3790748 DOI: 10.1371/journal.pone.0077414
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Annual incidence rates and observed mortality rates for hospitalizations with severe sepsis with organ failure between 1997 and 2008 in Taiwan.
(The nationwide SSC program was launched in 2004.)
Annual incidence rates, observed mortality rates and annual percentage change of mortality rates for hospitalizations with severe sepsis with organ failure between 1997 and 2008 in Taiwan.
| Year | No. of severe sepsis with organ failure | Annual incidence rate (per 1,000) | Observed mortality rates (%) | Annual percentage change of mortality rates (%) |
|---|---|---|---|---|
| 1997 | 40,856 | 1.88 | 46.3 | − |
| 1998 | 50,094 | 2.28 | 48.1 | 3.8 |
| 1999 | 59,181 | 2.68 | 48.4 | 0.7 |
| 2000 | 64,999 | 2.92 | 48.3 | -0.2 |
| 2001 | 72,762 | 3.25 | 48.5 | 0.3 |
| 2002 | 81,530 | 3.62 | 48.2 | -0.6 |
| 2003 | 88,712 | 3.92 | 47.9 | -0.6 |
| 2004 | 101,511 | 4.47 | 47.7 | -0.3 |
| 2005 | 110,927 | 4.87 | 46.7 | -2.2 |
| 2006 | 111,139 | 4.86 | 46.0 | -1.4 |
| 2007 | 119,006 | 5.18 | 46.0 | -0.2 |
| 2008 | 116,749 | 5.07 | 45.0 | -2.1 |
Characteristics, utilization rates of items of the surviving sepsis campaign (SSC) and outcomes are compared between before implementation of the SSC program (pre-intervention cohort, 2000-2003) and after implementation of the SSC program (post-intervention cohort, 2005-2008).
| Pre-intervention cohort (2000-2003) | Post-intervention cohort (2005-2008) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (n=14,848) | (n=24,858) | |||||||||
| Characteristics | n | (%) | n | (%) |
| Sig. | ||||
| Gender | 0.547 | |||||||||
| Male | 8810 | (59.3) | 14673 | (59.0) | ||||||
| Female | 6038 | (40.7) | 10185 | (41.0) | ||||||
| Age | <0.001 | *** | ||||||||
| 80- | 3707 | (25.0) | 7985 | (32.1) | ||||||
| 60-79 | 7066 | (47.6) | 10616 | (42.7) | ||||||
| 40-59 | 2514 | (16.9) | 4174 | (16.8) | ||||||
| 20-39 | 877 | (5.9) | 1173 | (4.7) | ||||||
| 0-19 | 684 | (4.6) | 910 | (3.7) | ||||||
| Charlson Index | <0.001 | *** | ||||||||
| 5- | 4596 | (31.0) | 9140 | (36.8) | ||||||
| 3-4 | 3417 | (23.0) | 5977 | (24.0) | ||||||
| 1-2 | 4787 | (32.2) | 6943 | (27.9) | ||||||
| 0 | 2048 | (13.8) | 2798 | (11.3) | ||||||
| No. of organ dysfunction | <0.001 | *** | ||||||||
| 4+ | 40 | (0.3) | 72 | (0.3) | ||||||
| 3 | 520 | (3.5) | 1093 | (4.4) | ||||||
| 2 | 2715 | (18.3) | 5329 | (21.4) | ||||||
| 1 | 11573 | (77.9) | 18364 | (73.9) | ||||||
| Organ dysfunction | ||||||||||
| Cardiovascular | 3163 | (21.3) | 5485 | (22.1) | 0.075 | |||||
| Hematologic | 647 | (4.4) | 965 | (3.9) | 0.020 | * | ||||
| Hepatic | 1218 | (8.2) | 1712 | (6.9) | <0.001 | *** | ||||
| Metabolic | 156 | (1.1) | 286 | (1.2) | 0.359 | |||||
| Neurologic | 913 | (6.1) | 1614 | (6.5) | 0.174 | |||||
| Renal | 3528 | (23.8) | 6647 | (26.7) | <0.001 | *** | ||||
| Respiratory | 9098 | (61.3) | 15886 | (63.9) | <0.001 | *** | ||||
| Utilization rates of items of surviving sepsis campaign | ||||||||||
| Initial resuscitation | ||||||||||
| Use of CVP | 5733 | (38.6) | 9482 | (38.1) | 0.355 | |||||
| Blood transfusion | 7610 | (51.3) | 12583 | (50.6) | 0.222 | |||||
| with packed RBC | 6758 | (45.5) | 11500 | (46.3) | 0.148 | |||||
| with FFP | 4331 | (29.2) | 6022 | (24.2) | <0.001 | *** | ||||
| Measure of blood lactate level | 720 | (4.8) | 3155 | (12.7) | <0.001 | *** | ||||
| Antibiotic therapy | ||||||||||
| Use of broad spectrum antibiotics | 6812 | (45.9) | 14251 | (57.3) | <0.001 | *** | ||||
| Use of diagnostic culture | 10460 | (70.4) | 20723 | (83.4) | <0.001 | *** | ||||
| Vasopressors | ||||||||||
| Use of Dopamine | 6417 | (43.2) | 9513 | (38.3) | <0.001 | *** | ||||
| Use of Norepinephrine | 1508 | (10.2) | 3617 | (14.6) | <0.001 | *** | ||||
| Use of steroid | 6404 | (43.1) | 12070 | (48.6) | <0.001 | *** | ||||
| Recombinant human activated protein C | ||||||||||
| Use of activated protein C | 0 | (0.0) | 16 | (0.1) | <0.001 | *** | ||||
| Mechanical ventilation | ||||||||||
| Use of ventilator | 8262 | (55.6) | 13848 | (55.7) | 0.900 | |||||
| Weaning attempts | 2063 | (13.9) | 4644 | (18.7) | <0.001 | *** | ||||
| Mean duration of ventilation ± SE | 15.1 | ± 0.4 | 14.8 | ± 0.3 | 0.122 | |||||
| Neuromuscular blockage | ||||||||||
| Use of muscle relaxant | 1340 | (9.0) | 2553 | (10.3) | <0.001 | *** | ||||
| Renal replacement therapy | ||||||||||
| Use of hemodialysis | 2329 | (15.7) | 4329 | (17.4) | <0.001 | *** | ||||
| Bicarbonate therapy | ||||||||||
| Use of sodium bicarbonate | 3711 | (25.0) | 5390 | (21.7) | <0.001 | *** | ||||
| Stress ulcer prophylaxis | ||||||||||
| Use of H2 blocker or PPI | 4634 | (31.2) | 9651 | (38.8) | <0.001 | *** | ||||
(n=39,706).
SE: standard error. NTD: New Taiwan Dollar. CVP: central venous catheterization. FFP: frozen fresh plasma. PPI: proton pump inhibitor
Sig.: p < 0.05: * p<0.01: ** p<0.001: ***
Figure 2Utilization rate changes for items in the SSC guidelines before and after the SSC program was implemented in Taiwan.
(pre-intervention cohort (2000-2003, before SSC program) vs. post-intervention cohort (2005-2008, after SSC program), n=39,706).
Figure 3Effects of utilization rate changes for items in the SSC guidelines on changes in mortality rates in Taiwan (pre-intervention cohort (2000-2003, before SSC program) vs. post-intervention cohort (2005-2008, after SSC program), n=39,706).